RCS - Nuformix PLC - Attendance at American Thoracic Society Congress

NuformixAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250519:nRSS1174Ja&default-theme=true

RNS Number : 1174J  Nuformix PLC  19 May 2025

Reach

 

19 May 2025

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Attendance at the American Thoracic Society Congress 2025 and presentation of
NXP002 data

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce, its attendance at the American Thoracic Society Congress, taking
place in San Francisco, USA, from 18 to 21 May 2025.

 

The positive results from the recent analysis of data from studies of NXP002
in a precision-cut lung slice ("PCLS") disease models using tissue from IPF
and autoimmune ILD patients will be presented on 21 May within the Wednesday
morning session titled "Drug Discovery and Development in IPF: Challenges and
Opportunities".

 

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to be
attending the ATS congress in San Francisco. We will have the opportunity to
progress discussions with potential licensing and development partners and
showcase the positive results from our recent analysis of NXP002's performance
in tissue from multiple IPF and autoimmune ILD patients.  This follows the
receipt of confirmation of eligibility for Orphan Drug Designation in IPF from
the EMA.  I look forward to providing further updates in due course as
appropriate."

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

About IPF

 

IPF is a chronic lung disease characterised by progressive tissue scarring
that prevents proper lung function. It is a progressive, fatal, age-associated
lung disease affecting approximately three out of every one hundred thousand
people in Europe. IPF typically presents in adults 65 or older and is usually
fatal within two to five years after diagnosis.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUWUNRVNUVAAR